Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVMD Revolution Medicines, Inc.

盘前交易 08-13 06:10:14 EDT

205.26

-0.29

-0.14%

盘前205.26

+0.000.00%

04:00 EDT

最高208.49	最低203.75	成交量117.59万
今开206.99	昨收205.55	日振幅2.31%
总市值439.95亿	流通市值414.99亿	总股本2.14亿
成交额2.42亿	换手率0.58%	流通股本2.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":205.26,"timestamp":1786564800000,"preClose":205.55,"halted":0,"volume":1175945,"hourTrading":{"tag":"盘前","latestPrice":205.26,"preClose":205.26,"latestTime":"04:00 EDT","volume":12,"amount":2461.24992,"timestamp":1786608018544,"change":0,"changeRate":0,"amplitude":0.001267},"delay":0,"changeRate":-0.0014108489418633932,"floatShares":202177310,"shares":214336418,"eps":-8.921187,"marketStatus":"盘前交易","change":-0.29,"latestTime":"08-13 06:10:14 EDT","open":206.99,"high":208.49,"low":203.75,"amount":241748174.26154998,"amplitude":0.02306,"askPrice":206.25,"askSize":1,"bidPrice":176.5,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-8.921187,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786627800000},"marketStatusCode":1,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":205.26,"preHourTrading":{"tag":"盘前","latestPrice":205.26,"preClose":205.26,"latestTime":"04:00 EDT","volume":12,"amount":2461.24992,"timestamp":1786608018544,"change":0,"changeRate":0,"amplitude":0.001267},"postHourTrading":{"tag":"盘后","latestPrice":205,"preClose":205.26,"latestTime":"19:48 EDT","volume":10294,"amount":2113291.734,"timestamp":1786578500903,"change":-0.26,"changeRate":-0.001267,"amplitude":0.023637},"volumeRatio":0.64274293973045,"impliedVol":0.536,"impliedVolPercentile":0.376},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"2658161961","title":"市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2360107325.USD","KURE","IDNA","LU0348723411.USD","IE00BZ199S13.USD","LU1861215975.USD","LU0724618433.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4141","LU0109394709.USD","LU0320765992.SGD","LU1251922891.USD","LU1983260115.SGD","LU1770034418.SGD","BK4605","IE00BJJMRZ35.SGD","LU1978683503.SGD","LU1854104046.USD","IE0009355771.USD","BK4585","LU1720051017.SGD","LU1720051108.HKD","BK4139","LU1548497426.USD","BBH","LU1861214812.USD","ON","LU0124384867.USD","BK1588","LU2298322129.HKD","LU2357305700.SGD","BK1583","LU0588546209.SGD","BK0239","BK4588","IE00BD6J9T35.USD","LU1854103824.USD","BK4512","IE00B2B36J28.USD","CANC","IE00BJT1NW94.SGD","06160","688235","IE0009354923.USD","LU1861219969.SGD","PTH","IE00BFMHRM44.USD","RVMD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965691?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU0588546209.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK1588","IE0009355771.USD","IE00B4R5TH58.HKD","KCAI","LU1969619763.USD","BK1583","LU0307460666.USD","ONC","IE0009354923.USD","BK4139","LU0109394709.USD","IDNA","LU0228659784.USD","IE0002141913.USD","LU0828237510.HKD","IE00BFTCPJ56.SGD","PTH","RVMD","BK1161","LU1251922891.USD","LU1303224171.USD","LU0320765992.SGD","LU1719994722.HKD","LU2328871848.SGD","KURE","VXUS","BK4526","BK4585","06160","IE00B2B36J28.USD","LU0889565916.HKD","LU1770034418.SGD","688235","BK0239","BBH","CANC","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950149","title":"百济神州与Revolution Medicines达成临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950149?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:40","pubTimestamp":1786405224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","BBH","IE00BJJMRZ35.SGD","CANC","BK4585","PTH","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00B2B36J28.USD","BK4588","BK4526","IE0009354923.USD","BK4139","IDNA","IE0009355771.USD","LU0889565916.HKD","ONC","RVMD","LU0109394709.USD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4526","LU2328871848.SGD","BD","BK1583","IE00B2B36J28.USD","LU0228659784.USD","ONC","06160","IE0009354923.USD","KURE","IE00BJT1NW94.SGD","LU0307460666.USD","BK1515","LU1969619763.USD","BK1500","CANC","BK4139","LU1770034418.SGD","603087","LU1251922891.USD","BK1588","LU0588546209.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU1719994722.HKD","BK1574","BK4588","LU0828237510.HKD","LU1303224171.USD","688235","IE0002141913.USD","IE0009355771.USD","IDNA","RVMD","LU0109394709.USD","09939","BK4585","159938","LU0320765992.SGD","PTH","BK1161","IE00B4R5TH58.HKD","BBH","BK0239","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189831237","title":"百济神州获Revolution Medicines四大资产在选定亚洲市场的独家授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1189831237","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189831237?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:05","pubTimestamp":1786356339,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）宣布，已获得Revolution Medicines, Inc.旗下四项核心资产在特定亚洲市场的独家权利。这一战略合作，标志着百济神州在亚洲关键区域的布局进一步深化。\n依据协议，百济神州将独家享有Revolution Medicines这四款创新药物在部分亚洲国家和地区的开发、商业化权益。此举不仅丰富了百济神州的肿瘤产品管线，也为其在亚洲市场的竞争力增添了强劲动力。交易的财务细节尚未披露，但市场分析人士普遍认为，此举对双方而言都是互利共赢的明智选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK0239","IE00B2B36J28.USD","IE0009354923.USD","PTH","LU0109394709.USD","IE00B4R5TH58.HKD","RVMD","LU0320765992.SGD","CANC","IDNA","BBH","IE00BFTCPJ56.SGD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142470173","title":"百济神州与Revolution Medicines合作：里程碑付款与分级版税权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1142470173","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142470173?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:04","pubTimestamp":1786356295,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）与Revolution Medicines, Inc.已达成合作，根据协议，双方将在合作区域内享有获得里程碑付款及分级版税的权利。这一安排标志着两家公司在共同开发与商业化方面迈出了重要一步，为各自带来了潜在的经济收益与战略协同。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE0002141913.USD","688235","LU0320765992.SGD","BBH","IE00BJT1NW94.SGD","BK0239","CANC","IDNA","IE0009355771.USD","IE00B2B36J28.USD","RVMD","IE00BFTCPJ56.SGD","PTH","LU0889565916.HKD","BK4139","IE00BJJMRZ35.SGD","IE0009354923.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657147096","title":"根据美国证券交易委员会文件披露，谷歌母公司Alphabet Inc.将其持有Revolution Medicines I","url":"https://stock-news.laohu8.com/highlight/detail?id=2657147096","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657147096?lang=zh_cn&edition=full","pubTime":"2026-08-07 18:07","pubTimestamp":1786097238,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1435385759.SGD","LU0511384066.AUD","LU0742534661.SGD","LU1670756490.USD","LU0784385170.HKD","LU0345769128.USD","LU0056508442.USD","LU2125154935.USD","LU0310799852.SGD","LU0302445910.USD","SGXZ81514606.USD","LU0426417589.USD","LU1935042488.USD","LU0187121727.USD","SKYY","LU0289960550.SGD","GOOW","LU1267930730.SGD","LU2244417387.USD","SG9999014567.USD","LU0477156797.USD","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","LU2125909247.SGD","BK4592","LU1989772923.USD","IE0034235295.USD","SG9999014880.SGD","LU0957791311.USD","LU0208291251.USD","LU0345774631.USD","LU0128525689.USD","IE00BYXW3230.USD","LU2023250843.SGD","LU2168564495.EUR","LU1571399168.USD","LU1823568750.SGD","IE0002141913.USD","LU2098885051.SGD","LU2430703095.HKD","SG9999014575.USD","LU0157215616.USD","LU2746668461.USD","GXPC","LU0345770308.USD","LU0823434583.USD","LU1145028129.USD","LU0276348264.USD","LU0077335932.USD","LU2247934214.USD","BK4533","LU0494093205.USD","LU0689472784.USD","LU0130103400.USD","BK4573","LU0417517546.SGD","LU0690374961.EUR","BK4538","IE00BDRTCR15.USD","LU0211327993.USD","LU0289739343.SGD","LU1699723380.USD","LU0061474960.USD","LU0211331839.USD","LU0823421416.USD","LU0316494557.USD","LU0128525929.USD","LU1496350502.SGD","LU2471134952.CNY","TRUC","LU2381873111.SGD","LU2362541513.USD","LU1303367103.USD","LU0198837287.USD","GOOP","LU1935042991.SGD","LU0312595415.SGD","LU1868836914.USD","IE0009354923.USD","LU1989764748.USD","GGLL","LU1244550577.SGD","IE00BQXX3D17.EUR","LU1003077747.HKD","BK4598","SG9999014559.SGD","IE00BMPRXQ63.HKD","LU0345768740.USD","LU0310800965.SGD","IE00BQXX3F31.USD","LU2065169927.USD","SGXZ31699556.SGD","LU0097036916.USD","LU2097829019.USD","SG9999014914.USD","LU0820561818.USD","LU0234572021.USD","LU0444973449.USD","LU0949170426.SGD","SG9999018857.SGD","LU1670627923.USD","LU2242650005.HKD","LU2023250330.USD","LU2168563687.JPY","LU1119994496.HKD","XLC","LU1868837136.USD","LU0648000940.SGD","LU0472753341.HKD","BK4579","LU0158827781.USD","LU1629891620.HKD","IE00BJTD4N35.SGD","LU2097344431.USD","LU0267386448.USD","LU0528227936.USD","LU1935042215.USD","IE00BN8TJ469.HKD","LU2462157665.USD","LU0314106906.USD","BK4139","IE00BMPRXR70.SGD","LU0211326839.USD","LU0823434740.USD","LU2471134879.HKD","BK4077","LU0320765059.SGD","LU1301847155.USD","LU1868836757.USD","LU2491050071.SGD","LU1868837300.USD","IE00BKDWB100.SGD","LU1804176565.USD","SG9999000418.SGD","LU0052756011.USD","LU0889566641.SGD","LU0124676726.USD","LU0029864427.USD","LTL","LU2592432038.USD","LU2462591277.SGD","LU0642271901.SGD","LU1585245621.USD","LU1868836591.USD","GGLS","LU1280957306.USD","IE00BLSP4239.USD","IE0000B7K699.USD","LU2264538146.SGD","LU2491049909.HKD","SNPE","IE00B19Z8X17.USD","IE0004091025.USD","LU0980610538.SGD","LU1551013425.SGD","LU0256863902.USD","LU2362540622.SGD","LU0320765992.SGD","LU0496365809.HKD","LU0170899867.USD","LU2275660780.HKD","LU2750360641.GBP","SG9999015952.SGD","LU2087625088.SGD","LU1066051498.USD","LU1066051225.USD","IE00B7SZLL34.SGD","LU2404859667.USD","LU0985320562.USD","IE00BHPRN162.USD","HK0000304805.HKD","BK4574","LU0094547139.USD","LU1066053197.SGD","LU1642822529.SGD","IE0034235188.USD","LU1880398471.USD","LU1989772840.SGD","LU0784383803.USD","LU1674673428.USD","LU2403377893.USD","IE0034235303.USD","IE000BZT7R73.USD","HK0000819398.USD","LU2362541273.HKD","LU1043141396.HKD","LU1720051017.SGD","LU2242649171.HKD","LU0345774391.USD","LU1951200564.SGD","LU2860962120.EUR","LU1323610961.USD","LU2250418816.HKD","LU0109394709.USD","LU0942090050.USD","LU1201861249.SGD","LU2357305700.SGD","HK0000914686.HKD","LU0048573561.USD","LU0661504455.SGD","GB00B4QBRK32.GBP","LU1153585028.USD","LU1645745479.HKD","LU1196500208.SGD","LU1506573853.SGD","LU2756315318.SGD","BK4588","LU1633808545.USD","LU1839511570.USD","LU0640476718.USD","LU1366333091.USD","SG9999017495.SGD","HK0000304797.USD","EFIV","IE00BJTD4V19.USD","IE00BLSP4452.SGD","IE00BK4W5L77.USD","LU0868494708.USD","SGXZ51526630.SGD","LU0345769631.USD","LU0175139822.USD","LU0683600562.USD","LU2168564065.EUR","LU2999663052.SGD","LU0477156953.USD","LU1121112475.USD","LU1674673691.USD","LU2168564149.EUR","LU1894683348.USD","LU1400636657.SGD","LU0011850046.USD","LU0154236417.USD","LU0792757196.USD","BK4503","LU2023250504.SGD","LU2092627202.USD","LU1202635105.USD","LU1670628061.USD","LU2756315664.SGD","LU1989764664.SGD","LU1267930227.SGD","LU1046421795.USD","LU0256863811.USD","LU0211326755.USD","LU1366192091.USD","IE000SO60NU8.SGD","LU0158827948.USD","LU2065170008.USD","LU1914381329.SGD","LU1923622614.USD","LU0138981039.USD","LU0882574139.USD","IE00B19Z9505.USD","XDAT","LU2420271590.USD","SG9999014542.SGD","LU0096362180.USD","IE00BBT3K403.USD","LU1267930573.SGD","LU1974910355.USD","RVMD","LU1815333072.USD","GOOX","LU1988902786.USD","LU0251142724.SGD","LU0069063385.USD","LU0265550359.USD","IE00BK4W5M84.HKD","LU2954938101.SGD","LU1221951046.USD","LU1852331112.SGD","IE00BFTCPJ56.SGD","LU2092937148.SGD","LU2028103732.USD","IE0009355771.USD","LU2360106780.USD","LU1116320901.HKD","LU0426412945.USD","BK4602","LU1235294995.USD","LU1880398554.USD","LU2471134523.USD","LU0976567544.SGD","IE0004086264.USD","LU2265009873.SGD","SG9999015358.SGD","IE00B4R5TH58.HKD","LU2211815571.USD","LU1951198990.SGD","SG9999014906.USD","LU0203345920.USD","LU2089283258.USD","ILDR","LU0787776722.HKD","LU2125154778.USD","LU2602419157.SGD","LU0444971666.USD","LU2077746001.SGD","LU0784385840.USD","LU2236285917.USD","LU0476273544.USD","LU0889565916.HKD","IE00BDCRKT87.USD","IE000F7OJYX1.SGD","LU0348723411.USD","LU0784384876.USD","LU2237438978.USD","LU0738911758.USD","IE00BKPKM429.USD","LU0868494617.USD","IE0002270589.USD","LU0289961442.SGD","BK4612","BK4527","LU2430703251.USD","LU1718418525.SGD","LU2750360997.AUD","LU1551013342.USD","IE00B19Z8W00.USD","LU0648001328.SGD","LU1935043023.USD","LU0130518102.USD","LU0342679015.USD","LU0957808578.USD","LU1201861165.SGD","IE00BWXC8680.SGD","LU2089284900.SGD","IE00B19Z3B42.SGD","LU0345770993.USD","LU0080751232.USD","SGXZ99366536.SGD","LU1923623000.USD","BBH","LU0553294199.USD","CANC","LU0689626769.HKD","LU1400636574.HKD","LU2063271972.USD","BK4576","LU1244550494.USD","LU1267930490.SGD","BK4514","SGXZ44715902.SGD","LU2106854487.HKD","LU2213496289.HKD","LU0203347892.USD","LU0174119429.USD","SG9999015341.SGD","LU1043141123.HKD","LU1430594728.SGD","LU0545039389.USD","LU2456880835.USD","LU1803068623.USD","GOOY","OGIG","VOX","LU0106261372.USD","IE00B19Z3581.USD","LU2417539215.USD","LU1261432733.SGD","LU2102340556.USD","PTH","LU1066051811.HKD","BK4561","LU0994945656.USD","LU1032955483.USD","LU2065171402.SGD","LU1084165304.USD","LU2746668974.SGD","IE000MB6IJN5.SGD","LU0061474705.USD","LU0211328371.USD","LU0210533765.USD","SG9999015945.SGD","BK4534","BK4543","LU0130102774.USD","LU0557290698.USD","LU1496350171.SGD","IE00BMPRXN33.USD","LU0149725797.USD","LU2023251221.USD","BK4585","LU0143551892.USD","LU2505996681.GBP","LU0466842654.USD","LU1221951129.SGD","LU0672654240.SGD","IDNA","LU0070302665.USD","LU0964807845.USD","LU2111349929.HKD","LU0323591593.USD","LU1267930813.SGD","IE00BJLML261.HKD","LU1720051108.HKD","SG9999015978.USD","LU1116320737.USD","LU0215105999.USD","SG9999014898.SGD","CQTM","LU0943347566.SGD","LU0251131958.USD","LU1894683264.USD","LU1791710400.SGD","SG9999018865.SGD","LU2360032135.SGD","LU0048584097.USD","BK4532","HK0000532082.HKD","LU0820561909.HKD","LU0107464264.USD","LU1815336760.USD","LU2404859741.USD","LU0320765489.SGD","LU0353189763.USD","LU0823421333.USD","IE00B2B36J28.USD","LU1778281490.HKD","LU0225283273.USD","LU2087621335.USD","BK4581","LU2271345857.HKD","LU0265550946.USD","LU0006306889.USD","IE00BQXX3C00.GBP","LU0130517989.USD","LU1400636491.USD","LU2054465674.USD","LU2462591350.SGD","LU0127658192.USD","CMAG","LU1316542783.SGD","LU0234570918.USD","LU1232071149.USD","LU2505996509.AUD","LU2125909593.SGD","IE00BFMHRM44.USD","IE00BKVL7J92.USD","LU2491050154.USD","LU0690374615.EUR","LU2471134796.USD","LU2168564222.USD","LU0057025933.USD","LU0314104364.USD","HK0000914660.USD","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","LU0354030438.USD","LU1791710582.SGD","METV","LU0353189680.USD","IE00BJT1NW94.SGD","SG9999015986.USD","FCOM","LU0109391861.USD","IE00BSNM7G36.USD","LU1917777945.USD","LU2097344357.USD","LU0354030511.USD","LU1548497426.USD","LU0708995401.HKD","LU1059921491.USD","LU2326559502.SGD","LU1935043536.SGD","LU2065171311.SGD","LU2191332357.HKD","LU0820562030.AUD","LU1064131342.USD","GOU","LU0708994859.HKD","GOOGL","IE00BD6J9T35.USD","LU2433249047.HKD","LU0310800379.SGD","GB00B4LPDJ14.GBP","IE000WAW04H5.SGD","LU0251132253.USD","IE0001KFT4U8.USD","LU0345768153.USD","LU1429558221.USD","BK4550","BK4566","LU0949170772.SGD","LU0061475181.USD","LU0070217475.USD","LU1244550221.USD","LU2430703178.SGD","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125314601","title":"异动解读｜Revolution Medicines盘中上涨5.23%，FDA受理新药申请叠加财报前市场预期升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1125314601","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125314601?lang=zh_cn&edition=full","pubTime":"2026-08-05 00:35","pubTimestamp":1785861308,"startTime":"0","endTime":"0","summary":"8月5日，Revolution Medicines盘中上涨5.23%，报191.99美元/股，成交额9810.16万美元。消息面上，FDA此前已正式受理公司核心管线药物Daraxonrasib用于既往治疗过的转移性胰腺癌的新药上市申请（NDA），标志关键监管里程碑。同时欧洲药品管理局亦启动分阶段审评加速评估。Wedbush将目标价上调至192.10美元并维持跑赢大盘评级。此外，公司当日盘后将发布季度财报，市场对RAS靶向药物商业化前景预期持续升温，多重催化剂共振推动股价上行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131945806","title":"异动解读｜Revolution Medicines盘中上涨5.02%，FDA受理胰腺癌新药上市申请叠加投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1131945806","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131945806?lang=zh_cn&edition=full","pubTime":"2026-07-31 03:12","pubTimestamp":1785438771,"startTime":"0","endTime":"0","summary":"7月31日，Revolution Medicines盘中上涨5.02%，报190.0美元/股，成交额2.3亿美元。消息面上，FDA已正式受理公司提交的Daraxonrasib新药上市申请，用于治疗既往接受过治疗的转移性胰腺癌患者，标志着药物进入实质性审评阶段。同时，Wedbush将公司目标价由181美元上调至192.10美元，维持\"跑赢大盘\"评级，分析师共识均价达203.85美元。此前该药物三期试验数据显示，中位总生存期延长一倍至13.2个月，欧洲药品管理局亦已启动分阶段加速审评，全球商业化前景进一步明朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117561795","title":"异动解读｜Revolution Medicines盘中上涨5.06%，核心药物NDA获FDA正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1117561795","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117561795?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:24","pubTimestamp":1784816691,"startTime":"0","endTime":"0","summary":"7月23日，Revolution Medicines盘中上涨5.06%，报192.3美元/股，成交额1.06亿美元。消息面上，FDA已正式受理公司核心候选药物Daraxonrasib的新药上市申请，适应症为既往接受过治疗的转移性胰腺癌。该受理标志着关键监管里程碑，意味着FDA已启动实质性审评流程。同日，Wedbush将公司目标价从181美元上调至192.10美元，维持\"跑赢大盘\"评级。Revolution Medicines成立于2014年，是一家临床阶段精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178535518","title":"Revolution Medicines新药Daraxonrasib获FDA受理，用于既往治疗过的转移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1178535518","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178535518?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:06","pubTimestamp":1784750800,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理Revolution Medicines, Inc.提交的新药上市申请（NDA），该申请旨在寻求批准其候选药物Daraxonrasib用于治疗既往接受过治疗的转移性胰腺癌患者。\n这一受理标志着该药物研发进程中的一个关键监管里程碑，意味着FDA已认定申请材料完整，并已启动实质性的审评流程。胰腺癌，尤其是转移性疾病，长期以来预后不佳，治疗选择有限，因此这一新疗法的审评进展备受业界关注。\n公司股价在消息公布后反应积极，市场正密切关注后续的审评时间表以及可能的批准前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0889565916.HKD","BK4139","IE00BFTCPJ56.SGD","CANC","PTH","IE0009355771.USD","IDNA","IE0002141913.USD","RVMD","BBH","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0109394709.USD","IE0009354923.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136893445","title":"异动解读｜Revolution Medicines盘前下跌5.11%，报172.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136893445","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136893445?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:32","pubTimestamp":1784277142,"startTime":"0","endTime":"0","summary":"7月17日，Revolution Medicines盘前下跌5.11%，报172.36美元/股，成交额4.49万美元。Revolution Medicines所在的生物科技行业中，个股中，艾伯维公司涨0.88%，吉利德科学涨0.72%，安进涨0.84%，福泰制药涨0.41%，再生元制药公司涨0.72%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症。公司核心管线daraxonrasib此前在转移性胰腺癌三期试验中展现显著总生存期获益，目前已进入EMA分阶段审评及FDA申报准备阶段，公司正积极搭建全球自主商业化团队。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175603747","title":"欧洲药品管理局启动分阶段审评，加速评估Revolution Medicines的Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=1175603747","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175603747?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:30","pubTimestamp":1783431047,"startTime":"0","endTime":"0","summary":"欧洲药品管理局已决定通过分阶段审评程序，加快对Revolution Medicines, Inc.（股票简称：RVMD）旗下在研药物Daraxonrasib的评估进程。此举旨在缩短该潜在疗法的审评时间，使其能更早惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","PTH","IE00BJJMRZ35.SGD","RVMD","IE0002141913.USD","BK4139","CANC","BBH","IE00BJT1NW94.SGD","LU0320765992.SGD","IE0009355771.USD","LU0889565916.HKD","IE00B2B36J28.USD","IDNA","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155723179","title":"异动解读｜Revolution Medicines盘中上涨5.07%，ESMO GI数据亮眼叠加收入预期上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1155723179","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155723179?lang=zh_cn&edition=full","pubTime":"2026-06-30 03:39","pubTimestamp":1782761955,"startTime":"0","endTime":"0","summary":"6月30日，Revolution Medicines盘中上涨5.07%，报191.32美元/股，成交额7.69亿美元。消息面上，公司在欧洲肿瘤内科学会胃肠道肿瘤年会上披露最新临床数据，第二款RAS抑制剂zoldonrasib联合标准化疗在一线胰腺癌中客观缓解率达82%，zoldonrasib联合daraxonrasib的无化疗方案二线治疗ORR达50%，数据大超预期。此前瑞银指出，若双药联合数据积极，公司胰腺癌收入有望提升20%至40%，并预计daraxonrasib将快速获批上市。此外，公司已启动Rasolute 305三期试验患者治疗，进一步拓展一线治疗布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121703894","title":"Revolution Medicines启动Rasolute 305患者治疗，评估Zoldonrasib联合化疗作为Ras G12d转移性胰腺癌一线疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1121703894","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121703894?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:00","pubTimestamp":1782216055,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. 已正式启动其名为Rasolute 305的三期临床试验的患者治疗工作。这项关键性研究旨在评估其候选药物Zoldonrasib与化疗联合方案，作为Ras G12d突变型转移性胰腺癌患者一线治疗的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0889565916.HKD","BK4139","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD","RVMD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0109394709.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167442691","title":"异动解读｜Revolution Medicines盘中下跌5.21%，报142.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167442691","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167442691?lang=zh_cn&edition=full","pubTime":"2026-06-10 23:23","pubTimestamp":1781104981,"startTime":"0","endTime":"0","summary":"6月10日，Revolution Medicines盘中下跌5.21%，报142.19美元/股，成交额1.28亿美元。Revolution Medicines所在的生物科技行业中，个股中，吉利德科学跌2.1%，Nuvalent涨0.1%，安进涨0.85%，艾伯维公司涨0.66%，Argenx SE跌0.06%。Revolution Medicines是一家临床阶段精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法，拥有基于结构的药物发现能力及针对RAS通路关键信号节点的深层管线。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113096257","title":"异动解读｜Revolution Medicines盘中下跌5.13%，ASCO大会胰腺癌数据利好兑现后股价高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1113096257","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113096257?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:39","pubTimestamp":1780411180,"startTime":"0","endTime":"0","summary":"6月2日，Revolution Medicines盘中下跌5.13%，报153.18美元/股，成交额1.91亿美元。消息面上，此前ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，该数据同步发表于《新英格兰医学杂志》，被视为RAS靶向治疗里程碑突破。受此利好驱动，公司股价此前夜盘及盘前累计涨幅已超15%，奥本海默同步上调目标价至195美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105705147","title":"异动解读｜Revolution Medicines盘中上涨5.11%，ASCO大会胰腺癌III期数据大超预期持续提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1105705147","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105705147?lang=zh_cn&edition=full","pubTime":"2026-06-02 02:52","pubTimestamp":1780339963,"startTime":"0","endTime":"0","summary":"6月2日，Revolution Medicines盘中上涨5.11%，报165.445美元/股，成交额7.53亿美元。消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。该数据首次将二线胰腺癌中位OS拉长至1年以上，被视为RAS靶向治疗的里程碑突破。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139903431","title":"异动解读｜Revolution Medicines盘前上涨15.38%，ASCO大会胰腺癌III期数据大超预期引爆市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1139903431","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139903431?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:02","pubTimestamp":1780300930,"startTime":"0","endTime":"0","summary":"6月1日，Revolution Medicines盘前上涨15.38%，报181.33美元/股，成交额43.73万美元。消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，该研究入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。公司同步推进daraxonrasib一线治疗及联合用药试验，商业化前景持续扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127581925","title":"异动解读｜Revolution Medicines夜盘上涨7.95%，ASCO大会RAS抑制剂胰腺癌数据引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1127581925","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127581925?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272081,"startTime":"0","endTime":"0","summary":"6月1日，Revolution Medicines夜盘上涨7.95%，报170.0美元/股，成交额1.31万美元。消息面上，ASCO大会即将集中展示公司核心品种daraxonrasib的III期RASolute 302研究数据。胰腺癌长期被视为最难攻克的癌种之一，5年相对生存率仅约13%，该数据被视为RAS靶向治疗在胰腺癌领域的里程碑突破，ASCO正式报告在即，市场提前反映乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":0.0403},{"period":"1month","weight":0.1158},{"period":"3month","weight":0.3733},{"period":"6month","weight":1.1312},{"period":"1year","weight":4.8213},{"period":"ytd","weight":1.577}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.06489},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}